Johnson & Johnson rode sales of the cancer treatment Darzalex and other key drugs to a better-than-expected second quarter, but exchange rates again pinched the health care giant’s 2022 forecast.
After trimming its forecast in April citing exchange rates, the company did so again Tuesday to a range below analyst expectations. Johnson & Johnson, which brings in nearly half of its sales from outside the United States, said foreign exchange rates delivered a $1.5 billion hit to sales in quarter.
The strong U.S. dollar is nearing parity with the euro for the first time in decades, and that can affect sales for companies that do a lot of international business. They have to convert those sales into dollars when they report earnings.
A stronger dollar decreases the value of those sales. It also gives foreign products a price edge in the United States.
J&J said Tuesday that it now expects adjusted earnings of $10 to $10.10 per share this year, down from the $10.15 to $10.35 it forecast in the spring.
Wall Street had been expecting earnings of $10.19 per share, according to FactSet.
In the second quarter for J&J, sales of the blood cancer treatment Darzalex jumped 39% to nearly $2 billion. Sales of J&J’s one-shot COVID-19 vaccine, which debuted last year, totaled $544 million, with only $45 million coming from the United States.
U.S. regulators in May strictly limited who can receive Johnson & Johnson’s COVID-19 vaccine due to the ongoing risk of rare but serious blood clots. That came a month after J&J said it was suspending sales projections for the vaccine, from which it doesn’t intend to profit.
Outside pharmaceuticals, which make up J&J’s biggest business, sales slipped for the company’s medical device and consumer health segments but grew slightly when not counting exchange rates.
J&J said last fall it will split off its consumer health business, which sells Band Aids and beauty products, into a separate, publicly traded company. That will allow the world’s largest maker of health care products to focus on pharmaceuticals and medical devices.
Chief Executive Officer Joaquin Duato told analysts on Tuesday that the company was on track to complete the separation next year.
Overall, J&J’s quarterly profit plunged 23% to $4.81 billion in the second quarter compared with last year's quarter, when earnings jumped as hospitals and the rest of the health care industry recovered from the initial impact of the pandemic.
Adjusted earnings per share totaled $2.59 and sales grew 3% to $24.02 billion.
Industry analysts expected earnings of $2.54 per share on $23.77 billion in revenue.
Shares of the New Brunswick, New Jersey, closed Tuesday down $2.54, or 1.5%, to $171.69.
The stock price has risen 0.4% so far this year while the Dow Jones industrial average, of which J&J is a member, has dropped 12.4%.
Follow Tom Murphy on Twitter: https://twitter.com/thpmurphy